Lund - Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee for the Annual General Meeting on May 5, 2020 has been appointed.
According to the instructions for the Nomination Committee adopted at the Annual General Meeting on May 9, 2019, the Nomination Committee for Alligator Bioscience's Annual General Meeting 2020 shall consist of four members, representing the three largest shareholders as of the last weekday in June, together with the Chairman of the Board. If the shareholder does not exercise his right to appoint a member of the nomination committee, the next largest shareholder shall be entitled to appoint a member of the nomination committee to the number of votes.
Based on the above, the Nomination Committee for the Annual General Meeting 2020 has been determined to consist of the following persons, who together represent approximately 20 percent of the number of shares and votes in the company as of the end of October 2019: Hans-Peter Ostler, representing Jonas Sjogren; Jan Lundstrom, representing Sunstone Life Science Ventures II K / S; Lars Bergkvist, representing Lars Spanberg and Peter Benson, Chairman of the Board.
Lars Bergkvist has been appointed Chairman of the Nomination Committee.
The Nomination Committee's task is to prepare and present proposals for the Chairman of the Annual General Meeting, the number of Board members elected by the Annual General Meeting, the Chairman and other members elected by the Board of Directors, fees and other remuneration to each of the Board members elected by the AGM and to the members of the Board of Auditors, , fees to the auditor as well as the election of the nomination committee or a decision on principles for appointing the nomination committee and decisions on instructions for the nomination committee.
Shareholders who wish to submit comments or submit proposals to the Nomination Committee may do so via email marked 'Att. Nominating Committee 'to email@example.com or via letter to Alligator Bioscience AB, Nominating Committee, Medicon Village, 223 81 Lund. In order for the Nomination Committee to consider a proposal, the proposal must have been submitted well in advance of the AGM, but no later than 31 January 2020.
The nomination committee's proposals will be presented in the notice of the AGM and on the company's website.
Tel: 046-540 82 06
The information was made available for publication on November 13, 2019, at the time of the above contact person. 10.30.
About Alligator Bioscience
Alligator Bioscience is a public Swedish biotechnology company that develops tumor-directed cancer immunotherapy. Alligator's project portfolio includes six drug candidates in clinical and preclinical development phase: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (in co-development with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development) by Shanghai Henlius Inc.). Alligator's shares are traded on Nasdaq Stockholm under the ticker 'ATORX'. The company was founded in 2001 and today has about 55 employees. The head office is located at Medicon Village in Lund, Sweden.